Pre-oxygenation With High-flow Nasal Cannula in Caesarian Section Under General Anesthesia

Summary

The investigators and other groups have demonstrated that high-flow nasal oxygen used during preoxygenation for emergency surgery is at least equally effective as preoxygenation compared to standard tight fitting mask. The investigators also have data from a recent study that indicates that high-flow nasal oxygen might decrease the risk of clinically relevant desaturation below 93% of arterial oxygen saturation.

The studies investigating the concept of high-flow nasal oxygen has up to this date excluded pregnant women. Pregnant woman is a patient group with known difficulties to maintain adequate saturation levels during apnoea. Due to smaller functional residual capacity their oxygen stores after preoxygenation are smaller compared to patients with a normal body mass index. The pregnant woman also have a higher oxygen demand and metabolism due to the growing placenta and the fetus. Pregnant women are therefore a patient group where a method that could prolong time until desaturation would be even more valuable and potentially could save lives.

Based on the above, the investigators now aim to conduct a clinical pilot study, where pregnant women undergoing caesarian section under general anesthesia are pre and perioxygenated with high-flow nasal oxygen. Data from that group will be compared with patients preoxygenated in a traditional manner with tight facemask. This study is done to evaluate an established technique on a patient category that in theory could gain a lot from it.

Conditions

• Pregnancy Related
• Anesthesia
• Oxygen Deficiency
• Cesarean Section Complications

Interventions

DEVICE

Nasal high flow oxygen

Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen

Sponsors & Collaborators

• Danderyds Hospital, Stockholm, Sweden

  collaborator UNKNOWN

• Stockholm South General Hospital

  collaborator OTHER

• Karlstad Central Hospital

  collaborator OTHER

• Östra Hospital

  collaborator OTHER

• Karolinska University Hospital

  lead OTHER

Principal Investigators

• Malin Jonsson Fagerlund · Karolinska University Hospital and Karolinska Insitutet

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-03-03

Primary Completion

2022-11-30

Completion

2022-11-30

Countries

• Sweden

Study Locations